Mutations affecting additional bona fide cancer genes were numerically more frequent in PTs than in adenosarcomas, such as TP53 (18% vs 5%), RB1 (18% vs 0), and EGFR (13% vs 0), although again these differences were not statistically significant (Fisher's exact tests, P > 0.05). The gene discussed is TP53; the disease is cancer.